ZyVersa Therapeutics, Inc. (ZVSA) intrinsic value & 10-year financials
ZyVersa Therapeutics, Inc. (ZVSA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.05
- Market cap
- $286.3K
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 334.4%
- Free cash flow (FY2025)
- —
ZVSA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$25.0M | -$4.18 | — | — | 1273.9% |
| FY2024 | — | -$9.4M | -$8.48 | — | — | -93.3% |
| FY2023 | — | -$98.3M | -$108.97 | — | — | -177.5% |
| FY2022 | — | — | — | — | — | — |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ZyVersa Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ZyVersa Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -27.4% ROIC.
ZyVersa Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
ZyVersa Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.